Top anti-arthritis drugs cause skin disease (embargo changed)March 31, 2005Members of the second most important family of drugs used to treat rheumatoid arthritis can cause serious dermatological conditions in a quarter of patients under treatment, reveals a study published today in the journal Arthritis Research and Therapy. Last year saw the withdrawal of frontline anti-arthritis drug Vioxx, which belongs to the cox-2 inhibitors family, when it was revealed that it poses a significant risk of heart attack and stroke. Similar findings were reported for other cox-2 inhibitors, although they are still on the market. This study shows that another family of anti-arthritis drugs, Tumour Necrosis Factoralpha (TNF-alpha) blocking agents, trigger skin conditions in 25% of patients undergoing treatment. TNF-alpha blocking agents are used to halt the process of joint destruction in patients with severe arthritis conditions. In the first study of the kind Marcel Flendrie and colleagues, from Radboud University Nijmegen Medical Centre in the Netherlands, followed a population of 289 patients who had been undergoing treatment for rheumatoid arthritis with TNF-alpha blocking drugs for a period of one to ten years. The drugs the patients had been taking included two anti-TNF-alpha antibodies, infliximab and adalimumab, and the TNF-alpha receptors etanercept and lenercept. The results of the study show that 25% of patients on therapy suffered from a dermatological condition that led them to visit a skin specialist. In a control group of patients who were not undergoing TNF-alpha blocking therapy and had less severe disease only 13% visited a dermatologist during the same period of time. The most frequent conditions that patients on therapy suffered from were: skin infections - 33 infections were recorded; eczema, which was diagnosed 20 times; and drug eruptions, which occurred mainly at the beginning of the treatment and were important enough for 7 patients to stop therapy. In addition, 12 patients were diagnosed with skin tumour and 9 with an ulcer. In total, 26% of the patients who developed a dermatological condition ceased their treatment due to the condition. "Dermatological conditions are a significant and clinically important problem in rheumatoid arthritis patients on TNF-alpha blocking therapy" conclude the authors. Dermatological conditions such as skin infections are common in rheumatoid arthritis patients, but the use of TNF-alpha blocking therapy might increase susceptibility, as TNF-alpha is a major player in the immune response to infections. Down regulating TNF-alpha might also trigger another type of immune response, which increases susceptibility to eczema, a condition not usually associated with rheumatoid arthritis. More prospective studies need to be carried out to investigate the incidence of skin disease in patients on therapy, but this study reveals clinically significant adverse effects of TNF-alpha blocking therapy. BioMed Central Limited |
|||||||||||||||||||||
| Related Arthritis Current Events and Arthritis News Articles Can EP4 agonist alleviate gastric lesions? Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding. Thoughtful words help couples stay fighting fit Couples who bring thoughtful words to a fight release lower amounts of stress-related proteins, suggesting that rational communication between partners can ease the impact of marital conflict on the immune system. Penn Study Provides First Clear Idea of How Rare Bone Disease Progresses An international team of scientists, led by researchers at the University of Pennsylvania School of Medicine, is taking the first step in developing a treatment for a rare genetic disorder called fibrodysplasia ossificans progressiva (FOP), in which the body's skeletal muscles and soft connective tissue turns to bone, immobilizing patients over a lifetime with a second skeleton. Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. Researchers find new way to attack inflammation in Graves' eye disease A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Common Pain Relievers May Dilute Power of Flu Shots With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system. Mending meniscals in children, improving diagnosis and recovery The meniscus is a rubber-like, crescent moon-shaped cartilage cushion that sits between the leg and thigh bone. Each knee has two menisci: one on the inside of the knee joint and one on the outside. Study finds link between childhood physical abuse and arthritis Adults who had experienced physical abuse as children have 56 per cent higher odds of osteoarthritis compared to those who have not been abused, according to a new study by University of Toronto researchers. Pain thresholds linked to inflammation and sleep problems in arthritis patients Despite recent advances in anti-inflammatory therapy, many rheumatoid arthritis (RA) patients continue to suffer from pain. URI research couple's method targets cancerous tumors Two University of Rhode Island associate professors, biophysicists Yana Reshetnyak and Oleg Andreev, have discovered a technology that can detect cancerous tumors and deliver treatment to them without the harming the healthy cells surrounding them, thereby significantly reducing side effects. More Arthritis Current Events and Arthritis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||